Antiviral Research

Papers
(The H4-Index of Antiviral Research is 38. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro1399
The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade1343
Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro685
Coronavirus membrane fusion mechanism offers a potential target for antiviral development606
Of chloroquine and COVID-19417
Type 1 interferons as a potential treatment against COVID-19392
Antiviral activities of type I interferons to SARS-CoV-2 infection331
Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern293
A potential role for integrins in host cell entry by SARS-CoV-2253
Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites251
The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer235
Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions227
Hepatitis B virus biology and life cycle146
Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors110
In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2110
Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2103
A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-1995
The omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters90
Hepatitis B virus cccDNA: Formation, regulation and therapeutic potential87
Ivermectin and COVID-19: A report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses86
Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017–201886
A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase68
Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance66
Targeting the multifunctional HBV core protein as a potential cure for chronic hepatitis B60
Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes59
Put a cork in it: Plugging the M2 viral ion channel to sink influenza54
Inhibition of herpes simplex virus by myricetin through targeting viral gD protein and cellular EGFR/PI3K/Akt pathway49
A robust SARS-CoV-2 replication model in primary human epithelial cells at the air liquid interface to assess antiviral agents46
An update on the progress of galidesivir (BCX4430), a broad-spectrum antiviral44
Benefit-risk assessment for brincidofovir for the treatment of smallpox: U.S. Food and Drug Administration's Evaluation43
Immunoglobulin fragment F(ab’)2 against RBD potently neutralizes SARS-CoV-2 in vitro43
Discovery of chebulagic acid and punicalagin as novel allosteric inhibitors of SARS-CoV-2 3CLpro43
Emetine suppresses SARS-CoV-2 replication by inhibiting interaction of viral mRNA with eIF4E42
Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2018–202041
Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection39
Very low levels of remdesivir resistance in SARS-COV-2 genomes after 18 months of massive usage during the COVID19 pandemic: A GISAID exploratory analysis39
Characterization of the antiviral effects of REP 2139 on the HBV lifecycle in vitro39
Current understanding of human herpesvirus 6 (HHV-6) chromosomal integration38
Remdesivir triphosphate can efficiently inhibit the RNA-dependent RNA polymerase from various flaviviruses38
0.079678058624268